Guggenheim Reduces PT on Eli Lilly and Company (LLY) to $1,161, Reiterates ‘Buy’ Rating

Core Insights - Eli Lilly and Company (NYSE: LLY) is recognized as a strong long-term investment option, with a focus on holding the stock for 20 years [1] Group 1: Price Target and Ratings - Guggenheim has reduced its price target for Eli Lilly from $1,163 to $1,161 while maintaining a 'Buy' rating, indicating confidence in the company's performance despite the slight adjustment [2] Group 2: FDA Designation and Oncology Pipeline - Eli Lilly announced that the FDA granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for adults with platinum-resistant ovarian cancer, which enhances the visibility of the company's oncology pipeline [3] - The designation accelerates development timelines and regulatory engagement, following positive Phase 1a/b data [3] Group 3: Clinical Trial Progress - At ASCO 2025 and ESMO 2025, Eli Lilly presented favorable responses across all dose levels and folate receptor alpha expression, demonstrating a strong tolerability profile with limited serious safety signals [4] - The asset is advancing into the global Phase 3 Framework-01 trial, positioning it as a potential differentiated entrant in the ovarian cancer market, which has high unmet needs [4] Group 4: Company Focus and Market Position - Eli Lilly is a global pharmaceutical company that develops medicines across various therapeutic areas, including diabetes, oncology, immunology, and neuroscience [5]